Background: Combination therapy with dexamethasone, remdesivir, and baricitinib has become a promising treatment for moderate or severe COVID-19; however, we have observed transient leukocytopenia in COVID-19 patients who received combination therapy.
Methods: Twelve consecutive COVID-19 patients treated with combination therapy were included in this retrospective analysis. Blood cell counts collected at the following three time points were analyzed: before the start of therapy (period 1), within 24 h of starting therapy (period 2), and within 48 h of period 2 (period 3).
Results: The leukocyte count significantly decreased in period 2 compared to period 1 and then significantly increased in period 3 without withdrawal of baricitinib. The neutrophil count transiently decreased in period 2 and recovered in period 3.
Conclusions: Clinicians should be aware of transient leukocytopenia in patients with COVID-19 during the early phase of combination therapy.
Keywords: Baricitinib; COVID-19; Leukocytopenia; Remdesivir.
Copyright © 2021 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.